ناقشت بنجاح طالبة الماجستير سوزان قواقزة من
قسم الصيدلة السريرية يوم الأربعاء 12/8/2015م بعنوان:
Potassium 3-beta-hydroxy-20-oxo
pregn-5-ene-17-alpha-yl sulfate (PHOZ), a promising potent inhibitor of glucose
regulated protein 78-KDa (GRP78
وقد ضمت لجنة المناقشة
الدكتور بلال الحسين رئيساً وعضوية كل من الدكتور قصي البلص والدكتور نزار مهيدات
والدكتور محمد خطاطبة والدكتورة عبله بصول كممتحن خارجي.
باسم صفحة أصدقاء كلية الصيدلة_ في جامعة العلوم
والتكنولوجيا الأردنية نبارك للطالبة سوزان قواقزه إتمامها درجة الماجستير في
الصيدلة السريرية بنجاح متمنين لها مزيدا من التقدم والنجاح.
* للاطلاع على ملخص الدراسة:
Background: Colorectal cancer (CRC) is an important
health problem all over the world. A great improvement in the screening and
early detection of CRC has been achieved. However, a new molecular prognostic
marker is largely required. Glucose regulated protein 78-Kda (GRP78) is the
central regulator of the endoplasmic reticulum (ER) and has an important role
in the proliferation, differentiation and resistance to chemotherapy in cancer
cells
Objectives: The aim of the present study was to
investigate the antiproliferative activity and the chemotherapy synergetic
effect of PHOZ against CRC cells
Methods: Cell viability was assessed by the 3-(4,
5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay method.
The apoptotic cells were measured using the propidium iodide method. Level of
GRP78 was evaluated by immunoblotting. Results: PHOZ induced a significant
reduction in CRC cell viability and has induced a significant synergism with chemotherapeutic
agents against CRC cells. These effects were largely attributed to the
inhibition of GRP78
Conclusion: Results suggest the possibility to use GRP78
inhibitor in combination with chemotherapeutic agents in patients diagnosed
with CRC
ليست هناك تعليقات:
إرسال تعليق